Conjugated multi-strain vaccine for meningitis

Menveo is the first conjugated multi-strain meningitis vaccine to be launched in the UK.

 It is licensed for active immunisation against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W135 and Y. The carrier protein used in Menveo, CRM197, is a naturally occurring nontoxic mutant of diphtheria toxin.

A pivotal randomised phase III trial conducted in the US compared Menveo to the US-licensed conjugated quadrivalent vaccine Menactra in 3539 healthy individuals aged 11–55 years.

Separate analyses showed Menveo to be superior to Menactra in adults (19–55 years of age) and adolescents (11–18 years of age) in terms of seroresponse rates (serogroup-specific serum bactericidal activity) 28 days after vaccination. Indeed, seroresponse rates were generally higher with Menveo than with Menactra.

Quadrivalent meningococcal vaccination should be considered in high-risk individuals travelling to the ‘meningitis belt' in sub-Saharan Africa and is compulsory for pilgrims and seasonal workers going to Mecca on the Hajj/Umra pilgrimage.

View Menveo drug record

Further information: Novartis Vaccines

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases